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Background: Anorexia nervosa (AN) is a mental disorder with grave burdens for affected individuals as well as for
the healthcare system. One of the strongest predictors of a poor outcome is a long Duration of Untreated Illness
(DUI), which is defined as the time between the onset of the disease and treatment initiation. Reducing the DUI is
an important step to optimize care of individuals with AN. In order to achieve this aim, systemic public health
interventions are necessary. Objective of this study is to evaluate a systemic public health intervention at Community
level aiming to reduce the DUI in individuals with AN.
Methods/design: The intervention includes the establishment of a network of health care professionals within the area
of eating disorders (EDs), the development of an internet-based treatment guide, the presentation of informative
short-films about EDs in cinemas and a corresponding poster campaign as well as a special outpatient clinic. For
the evaluating study a pre-post between-subject design is chosen. The DUI, and the duration until first contact
(DUC) with a health care professional, ED pathology as well as comorbidity are assessed before and after the systemic
intervention is carried out.
Discussion: The study attempts to provide evidence of the effectiveness of an ED-related systematic public health
intervention. Additionally, the study will lead to a better understanding of the DUI, which is essential in order to improve
care of individuals with AN.
Trial registration: Current Controlled Trials ISRCTN44979231; Registered 11 November 2011.
Keywords: Anorexia nervosa, Duration of Untreated Illness, Treatment Initiation, Systemic public health interventionBackground
Anorexia Nervosa (AN) is an eating disorder (ED) mainly
characterized by a refusal to maintain body weight, an in-
tense fear of weight gain as well as a distortion of body
perception. It can have serious adverse consequences on
physical as well as psychological health. Common con-
comitant effects include cardiac arrhythmias, electrolyte
imbalances, renal insufficiency, osteoporosis as well as se-
vere infections [1]. In addition, many patients with AN* Correspondence: a.gumz@uke.de
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unless otherwise stated.suffer from comorbid psychiatric disorders (e.g. [2-4]) with
anxiety and affective disorders being most frequent [5,6].
Compared with other mental disorders, AN occurs rela-
tively seldom with an average prevalence estimated at
0.3% [7]. However, with 0 to 22% the morbidity and mor-
tality rates are among the highest of any mental disease
[8,9]. In a 21-year follow-up study 14% of the patients died
from reasons directly related to AN [10]. Moreover, in
spite of low prevalence rates, AN generates high costs for
the health care systems - almost equivalent to those re-
ported for schizophrenia [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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affected individuals and the healthcare system an early
and effective treatment is indispensable. There is evi-
dence for the effectiveness of treatment methods for
AN [12]. Nevertheless, estimates show that only half of
the AN cases are detected in primary care settings [13]
and only one third of the cases detected receive treatment
[7]. There can be different reasons for AN- patients to re-
main untreated. Practitioners might not discover the dis-
order or patients might decide against a recommended
treatment due to the ego-syntonic nature of AN [14].
Even after a successful treatment initiation, there are
several factors that may have a negative impact on the
course of the disease. The most important predictors of a
poor outcome are a low Body-Mass-Index (BMI) as well
as severe psychological and social problems [10]. Some
studies report that a higher BMI at treatment initiation is
the strongest predictor of a successful course [15,16].
Therefore, treatment needs to be initiated before weight
loss becomes too severe and protracted [17]. This empha-
sizes another relevant outcome predictor: the Duration of
Untreated Illness (DUI). The DUI describes the time be-
tween the onset of an illness and the initiation of treat-
ment. There is evidence for a modest association between
DUI and outcome in schizophrenia [18,19] and some indi-
cation of an association in mood and anxiety disorders
[20,21]. The DUI may also play an important role in AN-
patients (e.g. [22,23]). It can be concluded that treatment
is more likely to be successful when patients have suffered
from AN for a shorter period of time [24]. A review con-
taining six studies from different Western countries found
the average DUI to be 1,78 years in patients with AN [25].
This is of great clinical concern as a long duration of AN
may be associated with severe complications such as in-
creased mortality [26].
So far, little research has been conducted on factors pre-
dicting the DUI in AN. Ackard and colleagues [27] re-
ported the duration of illness to be longer in middle-aged
(≥40 years) than in younger women (18–39 years). Health-
care system related aspects influencing the time between
symptom onset and treatment utilization are sufficient
information about diagnostic and treatment options,
availability as well as networking of different care givers
[28,29]. Especially general practitioners and pediatricians
need to have competence regarding diagnostic of and
treatment for EDs to facilitate and accelerate referral
into specialist care [30].
There are several interventions and resources available
to effectively treat AN [12] which are currently not used
to the full extent [7,13]. The reasons for the existing po-
tentials not being exploited fully may be found in individ-
uals as well as systemic structures. Thus, interventions
aiming to take this complexity into account have to be
multi-faceted as well. In the area of depressions, it hasbeen shown that systemic interventions are able to posi-
tively intervene in existing structures. With its four-level
intervention program for improving care of patients with
depression the “Regensburg Alliance against Depression”
succeeded in significantly decreasing suicide rates in
Regensburg [31].Objectives
The main objective of this project is to minimize the
DUI in individuals with AN. In order to achieve the aim
of the project, a systemic public health intervention is
carried out. It is hypothesized that this intervention de-
creases the DUI in individuals with AN.
This study is part of the project psychenet: Hamburg
network for mental health funded by the Federal Ministry
of Education and Research (BMBF). The purpose of psy-
chenet is to work on establishing innovative care models,
which aim to make decisive improvements to the pre-
vention, diagnosis and treatment of people with mental
illnesses in the Hamburg metropolitan region [32]. Psy-
chenet is coordinated by the Cluster Agency Healthcare
Hamburg (www.GWHH.de) in collaboration with the
University Medical Centre Hamburg-Eppendorf. It con-
sists of a total of eleven sub-projects. Since the network
was initiated in 2011, more than 80 scientific and med-
ical institutions, counselling centers, the Senate and the
Chamber of Commerce of the Free and Hanseatic City
of Hamburg, companies, as well as patients’ and rela-
tives’ associations have been acquired to participate.
Sub-project IX (Health network anorexia and bulimia)
focuses on the improvement of the effectiveness and ef-
ficiency of ED-specific care. It aims to optimize the use
of available resources as well as the connection of exist-
ing structures. The sub-project is divided into two dif-
ferent intervention arms. This article will provide an
overview about one intervention arm focusing on treat-
ment initiation in AN patients. An overview about the
second intervention arm (a randomized controlled trial
on the prevention of EDs in schools) will be described
elsewhere.Methods
Study design
For the study purpose, a pre-post between-subject design
was chosen. DUI, duration until first contact (DUC),
current ED pathology and comorbidity are measured be-
fore and after the implementation of the systemic inter-
vention. The pre-data collection takes place between
November 2012 and May 2013. Twelve months are
planned for the systemic intervention. The post-data col-
lection takes place between May 2014 and November
2014. Figure 1 illustrates the course of the data collection.
Figure 1 Course of data collection. Note. Recruitment for pre- and post-survey occurred within the same institutions offering evidence-based
treatment for AN based on the German S3-Guidelines for EDs [35].
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ethics committee of the Psychotherapist Chamber of
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Study procedures
Inclusion and exclusion criteria
In order to participate in the study, a signed informed
consent is necessary. Patients below 16 years are required
to provide additional informed consent from a parent or
legal guardian. Moreover, participants need to have female
sex, should be a minimum of ten years old and have a
treatment diagnosis of typical or atypical (one criterion
absent) AN according to the DSM-IV [33]. Furthermore
participants should currently receive their first ED-specific
in- or outpatient treatment or be current client of an
ED-specific counselling center. Exclusion criteria are
insufficient knowledge of the German language as well
as substantial organic or psychological complaints pre-
venting participation from the recruiting practitioner’s
point of view.
Recruitment
The recruitment is coordinated in cooperation with dif-
ferent ED-specific treatment settings in Hamburg and
adjacent areas, i.e. inpatient wards, day clinics, out-
patient departments and ED-specific counselling centers.
Included institutions offer evidence-based treatment for
AN based on the German S3-Guidelines for EDs [34]. A
total of eleven clinics, nineteen outpatient departments
and four counselling centers are asked to support the
project with recruiting participants. A special network
meeting is used to inform cooperating practitioners
about the study’s content, procedure, and recruitment as
well as to provide practitioners with study materials
(e.g. written information about the course of recruit-
ment, study design, inclusion and exclusion criteria as
well as informed consent forms and questionnaires forparticipants). During the study, cooperating practi-
tioners regularly receive phone calls to settle any ques-
tions and promote adherence.
Cooperating practitioners select eligible participants in
line with inclusion and exclusion criteria. Participants
found eligible are verbally informed about the aims and
procedure of the study and are additionally provided with
written material. In case of willingness to participate, par-
ticipants are asked to sign the informed consent. Practi-
tioners then hand out the questionnaire set, which is
described later in this paper. All cooperating practitioners
are required to return the completed questionnaires as
well as the signed informed consents to the research team.
Once all documents are complete, participants are con-
tacted for a structured telephone interview.
The procedure will be identical in the post-survey.
Participants who participated in the pre-survey are ex-
cluded from participation in the post-survey. Between
the two points of data collection the systemic interven-
tion takes place.
Modules of the intervention
Between 2011 and 2014 the research network psychenet:
Hamburg Network for Mental Health implements different
illness specific and general population oriented interven-
tions and evaluates the resulting systemic interventions.
The psychenet sub-project “Healthcare Network Anorexia
and Bulimia nervosa” establishes a systemic ED-specific
intervention containing the following components:
 The establishment of a network of health care
professionals within the area of EDs
 The development of an internet-based treatment
guide for EDs
 The presentation of informative short-films about
EDs in several cinemas as well as a corresponding
poster campaign
 A special outpatient clinic
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care professionals within the area of EDs. Practitioners
from different settings with a medical and/or a back-
ground in clinical psychology regularly meet to exchange
scientific knowledge as well as clinical experiences con-
cerning AN treatment. The internet-based treatment
guide (www.essstoerungen.psychenet.de) comprises in-
formation about EDs in general as well as treatment
options and contact information of ED-specialized in-
and outpatient institutions. The recommendations are
based on the German S3-Guidelines for EDs [34]. The
guide addresses individuals suffering from AN, relatives
and healthcare professionals. In order to reach patients
with a migration background as well, it is translated
into English and Turkish. Components of the systemic
intervention targeting the general population are the
presentation of a short-film (see www.youtube.com/
watch?v=6VPvCp_WWvI&index=2&list=PLF8DFEFE29
B837EFC) in cinemas as well as a corresponding poster
campaign. The poster-campaign comprises citations of
the principal performer of the short-film with an eye-
portrait and a short note about the prevalence of men-
tal illness as well as a reference towards the main
homepage (www.psychenet.de).
Variables and instruments
The data is collected in a two-stage course of action with
an antecedent questionnaire followed by a telephone
interview. The questionnaire contains standardized in-
struments to measure ED pathology and comorbidity, as
well as a set of questions concerning sociodemographic
information, disorder onset and the initiation of treat-
ment. The telephone consultation is started off with a
diagnostic interview reviewing AN diagnosis by using
the Structured Clinical Interview for DSM-IV SCID [35].
Then, questions regarding the onset of the disorder and
the initiation of treatment follow to verify information
collected from the questionnaire. The onset of the dis-
order is confirmed by requesting information about the
beginning of weight loss, beginning of fear to gain
weight, beginning of distortion of the body perception and
the initial absence of the menstruation. In an exploratory
part reasons for the individual DUI are explored.
Duration of untreated illness (DUI)
The DUI is understood as the number of months be-
tween illness onset and the initiation of an ED-specific
treatment. Onset of the disease is conceptualized as the
first occurrence of all symptoms of typical or atypical
AN as described above.
Duration until first contact with healthcare system (DUC)
The duration until first contact (DUC) is conceptualized
as the number of months between illness onset and thefirst contact with the healthcare system due to ED-
related issues initiated either by the patient or the practi-
tioner. Before starting an ED-specific treatment, patients
often have several initial contacts with healthcare profes-
sionals or advice centers. The variable DUI can not take
these contacts into account because it is defined as the
duration until the initiation of a guideline-based treat-
ment. The DUC is meant to improve the understanding
of the processes preceding treatment initiation. The
questionnaire lists different potential therapeutic settings
for AN (inpatient, day-clinic, outpatient, ED-specific
counselling) and assesses which of these have been con-
sulted to get information and/or support concerning AN
and, in each case, when the first contact took place.ED pathology
ED pathology is measured by the BMI in combination
with the German version of the Eating Disorder Examin-
ation Questionnaire EDE-Q [36]. The BMI is calculated
from body weight and height. Current weight is re-
quested in the questionnaire as well as in the telephone
interview. Additionally, weights at disorder onset, at
treatment initiation as well as at point of lowest weight
are assessed in the telephone interview. Given the
community-based character of the present study, it is
not feasible to get externally validated weight measure-
ments for all participants. Additionally, since patients
with AN in in- and outpatient treatment institutions are
weighted weekly, self-reported weight will be considered
adequate. The EDE-Q assesses specific ED psychopath-
ology on four subscales, which are restraint, eating con-
cern, weight concern, and shape concern. For patients
below the age of sixteen, the child version Ch-EDE-Q,
[37,38] is used. The psychometric criteria of the EDE-Q
are satisfactory. Objectivity is given and the test is very
reliable with an intern consistency of α = .97 and a
retest-reliability of r = .88. Validity could be confirmed as
well [36].Comorbidity
Comorbid psychopathology is assessed by the depression
module of the Patient Health Questionnaire (PHQ-9,
[39-41]) and the Generalized Anxiety Disorder Scale
(GAD-7, [42]). The PHQ-9 is a self-assessment scale con-
sisting of nine items. It is able to establish provisional de-
pressive disorder diagnoses and grade depressive symptom
severity [43]. There is strong evidence for the reliability of
the instrument with an intern consistency of α = .89 and a
retest-reliability of r = .84 [44]. The GAD-7 is a self-
assessment anxiety scale consisting of seven items. It has
good reliability as well as criterion, construct, factorial,
and procedural validity [42,45].
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The questionnaire includes sociodemographic and con-
trol variables, such as age, gender, marital status, educa-
tional level, migration background, housing situation
and occupational activity. At post assessment, patients
are asked to indicate any contact with parts of the sys-
temic interventions from psychenet. In case of positive
response, further questions clarify which of the ED-
specific interventions were recognized and if treatment
initiation is subjectively eased by these interventions.
Sample size/power calculation
Based on former international studies [25] with an aver-
age DUI of 19 months and an effect size of 0.4, we con-
sidered a DUI reduction of 4.8 months or 25% as clinically
relevant. Thus, for a two-sided type-I error of 5% two
samples with 100 participants each are needed to reach
statistically significance with a power of 80%.
Primary outcome
The primary outcome is the DUI, defined as the time in
months between the onset of AN and first specific
treatment.
Secondary outcome
As secondary outcome, DUC, current ED pathology as
well as comorbid depressive or anxious psychopathology
are assessed. Depression and anxiety are the most fre-
quent comorbid psychiatric disorders accompanying AN
(e.g. [5,6]).
Study hypotheses
It is hypothesized that the systemic intervention of psy-
chenet decreases the DUI in the post-group compared to
the pre-group. As described above it is of great relevance
to detect and treat individuals with AN sooner. Next to
individual factors such as age [27] there are systemic as-
pects like sufficient information, availability and net-
working of different components of the health care
system influencing patient flow into ED-specific care.
The intervention focuses on spreading information
about EDs, informing about paths to treatment, improv-
ing the networking of different healthcare professionals
and extending the offer by establishing a special out-
patient clinic. Therefore, it seems reasonable to assume
that the systemic intervention decreases the duration
until an ED-specific treatment is initiated. For the same
reasons it is hypothesized that the systemic intervention
decreases the DUC. Moreover, it is assumed that the sys-
temic intervention leads to a reduced ED pathology as
well as a reduced comorbidity with depression and anx-
iety at the beginning of treatment. It is further suspected
that this effect is mediated by the DUI. An earlier inter-
vention and a shorter duration of illness prior to treatmentinitiation may lead to a reduced severity of AN and a
reduced comorbidity because treatment starts before a
chronification can occur. Therefore, it is conceivable
that the expected shorter DUI in the post-group leads
to a decreased ED pathology and comorbidity at treat-
ment initiation. Due to the lack of previous research
these hypotheses will be analyzed exploratorily.
To display them at a glance, the hypotheses of the
study are:
 The systemic intervention decreases the DUI in the
post-group compared to the pre-group.
 The systemic intervention decreases the DUC in the
post-group compared to the pre-group.
 The systemic intervention decreases the ED
pathology at treatment initiation in the post-group
compared to the pre-group via DUI.
 The systemic intervention decreases the comorbidity
with depression and anxiety at treatment initiation
in the post-group compared to the pre-group via
DUI.
Figure 2 illustrates the expected impact of the systemic
intervention on the primary and secondary outcome
parameters.
Handling of missing values
Participants who appear unavailable for the telephone
interview will be regarded as withdrawal. Analyses will
be performed on completers due to the exploratory ap-
proach of the study. Additionally, sensitivity analyses
using imputed data (fully conditional specification [46])
will be conducted.
Statistical analyses
In order to test the primary hypotheses regarding change
vs. no change from pre to post assessment univariate
multiple regression analysis with the dependent variables
DUI and DUC as well as the independent variable period
of assessment will be conducted. Additionally, recruit-
ment setting will be included as random control variable
whereas age and contact with the systematic intervention
will be taken into account as a fixed control variable. Stat-
istical significance will be taken two-sided p <0.05
throughout and regression coefficient with 95% confi-
dence intervals (CI) will be used to express the uncer-
tainty in the data.
Discussion
This study is a pre-post study that examines the evalu-
ation of a systemic public health intervention for EDs.
The systemic intervention contains the establishment of
a network of health care professionals within the area of
EDs, the publication of a treatment guide for patients,
Figure 2 Expected impact of the systemic intervention on the primary and secondary outcome parameters.
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concerning EDs by short-films and posters as well as the
establishment of a special outpatient clinic. It is expected
that the systemic intervention decreases the time be-
tween the onset of AN and the first contact with health-
care system as well as the beginning of an ED-specific
treatment. It is further assumed that the systemic inter-
vention reduces ED pathology and comorbidity at treatment
initiation. Currently, there is no comparable intervention in
the field of EDs.
The value of the intervention must be classified as
high since a long DUI in AN is one of the strongest pre-
dictors of a poor outcome [16]. Evidence-based interven-
tions (e.g. [47]) have to be initiated at an early stage of
the illness to develop the full effectiveness. Reducing the
DUI is one important step to improve patient flow into
special health care in patients with AN. Moreover, the
intervention plans to improve the networking of differ-
ent instances of the health care system. Use of existing
resources is increased, which could on a long-term basis
lead to a reduction of the high costs for AN treatment
[11]. At present, evidence-based treatments for AN
[12] are not utilized sufficiently early and targeted
[7,13,25,48].
The study aims to evaluate the systemic intervention,
which is, next to the value of the intervention itself, of
great interest for further public health interventions.
Assessing the DUI and additionally the DUC may also
lead to a better understanding of the period during the
time until the first ED-specific treatment is initiated.
In spite of the huge demand for such evaluated inter-
ventions, some limitations to this study have to be men-
tioned: Since this project is a systemic public health
intervention, the implementation of a Randomized
Controlled Trial (RCT) is not feasible. Therefore, it isproblematic to control confounding factors and make
causal conclusions. However, this limitation can be attrib-
uted to the aims of the project, which leaves no option
of implementing a RCT. Due to the complexity of the
systemic intervention it is further not realizable to con-
duct a dismantling investigation. It is assumed that some
parts of the intervention act unconsciously. Therefore an
entire understanding of the underlying dependencies
will not be possible. Moreover, it is decided to exclude
male patients from participation - admittedly at the ex-
pense of generalization of the results. The reasons for
this decision can be found in the low prevalence of
AN in males. It has to be noted that there is a lack of
standardized measures assessing DUI and DUC. This
makes it necessary to develop a new measure for the pur-
poses of the study. Additionally, the variables of interest
mainly can only be assessed retrospectively. To counteract
a possible distortion, self-reported data is reviewed in the
telephone interview. In addition, it has to be considered
that a prospective study would not be feasible due to the
low prevalence of AN. There are some further limitations
concerning the recruitment of the participants. There may
be an adherence bias of the cooperating practitioners lead-
ing to different participation rates. There may be also a se-
lection bias: Chronified patients with extremely low body
weight may display a very long DUI but may be excluded
due to their current physical status. The consequence may
be an underestimation of the average DUI in the sample.
Since there hasn’t been a comparable intervention in
the field of AN, some hypotheses have to stay explora-
tory. However, the effectiveness of public health inter-
ventions in general could be shown already (e.g. [31]). In
the field of EDs the psychenet intervention and its evalu-
ation will gain new knowledge about the DUI and factors
influencing this period. Also, the successful implementation
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working of different health care professionals and facilitate
patients’ flow into specialist care.
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